Ovulation induction in IVF

Minerva Ginecologica

Volumn 63, Issue 2, 2011, Pages 137-155

  Oehninger, S ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Fertilization in vitro; Gonadotropin releasing hormone; Live birth; Ovulation induction

Indexed keywords

ALBUMIN; AROMATASE INHIBITOR; CABERGOLINE; CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; CORIFOLLITROPIN ALFA; DESOGESTREL; ESTRADIOL; ETHINYLESTRADIOL; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADOTROPIN; GROWTH HORMONE; HUMAN MENOPAUSAL GONADOTROPIN; INHIBIN B; LUTEINIZING HORMONE; METFORMIN; MUELLERIAN INHIBITING FACTOR; ORAL CONTRACEPTIVE AGENT; RECOMBINANT CHORIONIC GONADOTROPIN; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE;

ADD ON THERAPY; ADJUVANT THERAPY; ANDROGEN THERAPY; AUTOTRANSPLANTATION; BREAST CANCER; CLINICAL PROTOCOL; CONTROLLED OVARY HYPERSTIMULATION; CRYOPRESERVATION; DIAGNOSTIC ACCURACY; DRUG DOSE COMPARISON; DRUG MEGADOSE; ECHOGRAPHY; EMBRYO TRANSFER; EPIGENETICS; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FOLLICULAR PHASE; FOLLOW UP; GENOME IMPRINTING; GONADOTROPIN RELEASE; GRANULOSA CELL; HORMONAL REGULATION; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; HYPOGONADOTROPIC HYPOGONADISM; LOW DRUG DOSE; MENSTRUAL CYCLE; MULTICENTER STUDY (TOPIC); MULTIPLE PREGNANCY; OOCYTE MATURATION; ORAL CONTRACEPTION; OVARIAN RESERVE; OVARY FOLLICLE; OVARY FOLLICLE DEVELOPMENT; OVARY FOLLICLE MATURATION; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREDICTIVE VALUE; PREGNANCY OUTCOME; PREGNANCY RATE; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCREENING TEST; SINGLE DRUG DOSE; STEROIDOGENESIS; SURVIVAL RATE; TRANSVAGINAL ECHOGRAPHY; VITRIFICATION;

FEMALE; FERTILIZATION IN VITRO; HUMANS; OVULATION INDUCTION;

EID: 79959809247     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Nygren KG, Andersen AN. Assisted reproductive technology in Europe, 1999. Results generated from European registers by ESHRE. Hum Reprod 2002;17:3260-74.
2. Schieve LA, Devine O, Boyle CA, Petrini JR, Warner L. Estimation of the contribution of non-assisted reproductive technology ovulation stimulation fertility treatments to US singleton and multiple births. Am J Epidemiol 2009;170:1396-407.
3. Santos MA, Kuijk EW, Macklon NS. The impact of ovarian stimulation for IVF on the developing embryo. Reproduction 2010;139:23-34.
4. Fortunato A, Tosti E. The impact of in vitro fertilization on health of the children: an update. Eur J Obstet Gynecol Reprod Biol [In press].
5. Muasher SJ, Garcia JE, Rosenwaks Z. The combination of follicle-stimulating hormone and human menopausal gonadotropin for the induction of multiple follicular maturation for in vitro fertilization. Fertil Steril 1985;44:62-9. (Pubitemid 15000549)
6. Arsian M, Bocca S, Mirkin S, Barroso G, Stadtmauer L, Oehninger S. Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth Carr. Fertil Steril 2005;84:555-69. (Pubitemid 41317707)
7. Jones GS, Garcia JE, Rosenwaks Z. The role of pituitary gonadotropins in follicular stimulation and oocyte maturation in the human. J Clin Endocrinol Metab 1984;59:178-80. (Pubitemid 14087548)
8. Jones GS, Acosta AA, Garcia JE, Bernardus RE, Rosenwaks Z. The effect of follicle-stimulating hormone without additional luteinizing hormone on follicular stimulation and oocyte development in normal ovulatory women. Fertil Steril 1985;43:696-702.
9. Muasher SJ, Oehninger S, Simonetti S, Matta J, Ellis LM, Liu HC et al. The value of basal and/or stimulated serum gonadotropin levels in prediction of stimulation response and in vitro fertilization outcome. Fertil Steril 1988;50:298-307.
10. Toner JP, Philput CB, Jones GS, Muasher SJ. Basal follicle-stimulating hormone level is a better predictor of in vitro fertilization performance than age. Fertil Steril 1991;55:784-91.
11. Scott RT, Toner JP, Muasher SJ, Oehninger S, Robinson S, Rosenwaks Z. Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Fertil Steril 1989;51:651-4.
12. Jain T, Soules MR, Collins JA. Comparison of basal follicle-stimulating hormone versus the clomiphene citrate challenge test for ovarian reserve screening. Fertil Steril 2004;82:180-5. (Pubitemid 38968796)
13. Al-Azemi M, Killick SR, Duffy S, Pye C, Refaat B, Hill N et al. Multi-marker assessment of ovarian reserve predicts oocyte yield after ovulation induction. Hum Reprod [In press].
14. Broer SL, Dólleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJ. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update 2011;17:46-54.
15. Riggs RM, Duran EH, Baker MW, Kimble TD, Hobeika E, Yin L et al. Assessment of ovarian reserve with anti-Mullerian hormone: a comparison of the predictive value of anti-Mullerian hormone, folliclestimulating hormone, inhibin B, and age. Am J Obstet Gynecol 2008;199:202.
16. Riggs R, Kimble T, Oehninger S, Bocca S, Zhao Y, Leader B et al. Anti-Müllerian hormone serum levels predict response to controlled ovarian hyperstimulation but not embryo quality or pregnancy outcome in oocyte donation. Fertil Steril 2011;95:410-2.
17. Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr Rev 2009;30:465-93.
18. Deutch TD, Joergner I, Matson DO, Oehninger S, Bocca S, Hoenigmann D et al. Automated assessment of ovarian follicles using a novel three-dimensional ultrasound software. Fertil Steril 2009;92:1562-8.
19. Hugues JN. Ovarian stimulation for assisted reproductive technologies. In: Vayena E, Rowe PJ, Griffin PD, eds. Current practices and controversies in assisted reproduction. Geneve: World Health Organization; 2002. p. 102-25.
20. D'Angelo A, Amso N. "Coasting" (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2002, CD002811.
21. D'Angelo A, Amso N. Embryo freezing for preventing Ovarian Hyperstimulation Syndrome. Cochrane Database Syst Rev 2002;CD002806.
22. Arslan M, Bocca S, Jones E, Mayer J, Stadtmauer L, Oehninger S. Effect of coasting on the implantation potential of embryos transferred after cryopreservation and thawing. Fertil Steril 2005;84:867-74. (Pubitemid 41414574)
23. Gonen Y, Balakier H, Powell W, Casper RF. Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab 1990;71:918-22.
24. Youssef MA, Van der Veen F, Al-Inany HG, Griesinger G, Mochtar MH, van Wely M. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst Rev 2010;11:CD008046.
25. DiLuigi AJ, Engmann L, Schmidt DW, Maier DB, Nulsen JC, Benadiva CA. Gonadotropin-releasing hormone agonist to induce final oocyte maturation pre vents the development of ovarian hyperstimulation syndrome in high-risk patients and leads to improved clinical outcomes compared with coasting. Fertil Steril 2010;94:1111-4.
26. Centers for Disease Control and Prevention. 2009 Assisted Reproductive Technology and Success Rates. National Summary and Fertility Clinic Reports 2007.
27. Mirkin S, Nikas G, Hsiu JG, Díaz J, Oehninger S. Gene expression profiles and structural/functional features of the peri-implantation endometrium in natural and gonadotropin-stimulated cycles. J Clin Endocrinol Metab 2004;89:5742-52. (Pubitemid 39523132)
28. Dowling-Lacey D, Jones E, Mayer J, Bocca S, Stadtmauer L, Oehninger S. Elective transfer of two embryos: reduction of multiple gestations while maintaining high pregnancy rates. J Assist Reprod Genet 2007;24:11-5. (Pubitemid 46213646)
29. Min JK, Hughes E, Young D, Gysler M, Hemmings R, Cheung AP et al. Elective single embryo transfer following in vitro fertilization. J Obstet Gynaecol Can 2010;32:363-77.
30. Gelbaya TA, Tsoumpou I, Nardo LG. The likelihood of live birth and multiple birth after single versus double embryo transfer at the cleavage stage: a systematic review and meta-analysis. Fertil Steril 2010;94:936-45.
31. Pandian Z, Bhattacharya S, Ozturk O, Serour G, Templeton A. Number of embryos for transfer following in-vitro fertilisation or intra-cytoplasmic sperm injection. Cochrane Database Syst Rev 2009;(2):CD003416.
32. Toner JP, Brzyski RG, Oehninger S, Veeck LL, Simonetti S, Muasher SJ. Combined impact of the number of preovulatory oocytes and cryopreservation on IVF outcome. Hum Reprod 1991;6:284-9.
33. Jones HW Jr, Jones D, Kolm P. Cryopreservation: a simplified method of evaluation. Hum Reprod 1997;12:548-53.
34. Oehninger S, Mayer J, Muasher S. Impact of different clinical variables on pregnancy outcome following embryo cryopreservation. Mol Cell Endocrinol 2000;169:73-7. (Pubitemid 32063302)
35. Riggs R, Mayer J, Dowling-Lacey D, Chi TF, Jones E, Oehninger S. Does storage time influence postthaw survival and pregnancy outcome? An analysis of 11,768 cryopreserved human embryos. Fertil Steril 2010;93:109-15.
36. Dowling-Lacey D, Mayer JF, Jones E, Bocca S, Stadtmauer L, Oehninger S. Live birth from a frozen-thawed pronuclear stage embryo almost 20 years after its cryopreservation. Fertil Steril [In press].
37. Nagy ZP, Chang CC, Shapiro DB, Bernai DP, Kort HI, Vajta G. The efficacy and safety of human oocyte vitrification. Semin Reprod Med 2009;27:450-5.
38. Wennerholm UB, Söderström-Anttila V, Bergh C, Aittomäki K, Hazekamp J, Nygren KG et al. Children born after cryopreservation of embryos or oocytes: a systematic review of outcome data. Hum Reprod 2009;24:2158-72.
39. Daya S, Gunby J, Hughes EG, Collins JA, Sagle MA. Follicle-stimulating hormone versus human menopausal gonadotropin for in vitro fertilization cycles: a meta-analysis. Fertil Steril 1995;64:347-54.
40. Daya S, Gunby J. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction. Hum Reprod 1999;14:2207-15. (Pubitemid 29425401)
41. Agrawal R, Holmes J, Jacobs HS. Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis. Fertil Steril 2000;73:338-43. (Pubitemid 30060370)
42. van Wely M, Westergaard LG, Bossuyt PM, van d V. Effectiveness of human menopausal gonadotropin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis. Fertil Steril 2003;80:1086-93.
43. Jee BC, Suh CS, Kim YB, Kim SH, Moon SY. Clinical efficacy of highly purified hMG versus recombinant FSH in IVF/ICSI cycles: a meta-analysis. Gynecol Obstet Invest 2010;70:132-7.
44. Filicori M, Cognigni GE, Taraborrelli S, Spettoli D, Ciampaglia W, de Fatis CT et al. Luteinizing hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome. J Clin Endocrinol Metab 1999;84:2659-63.
45. Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod 2000;15:1003-8. (Pubitemid 30251290)
46. Hillier SG. Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Hum Reprod 1994;9:188-91. (Pubitemid 24076735)
47. Loumaye E, Engrand P, Shoham Z, Hillier SG, Baird DT. Clinical evidence for an LH 'ceiling' effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation. Hum Reprod 2003;18:314-22.
48. Cabrera RA, Stadtmauer L, Mayer JF, Gibbons WE, Oehninger S. Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone. Fertil Steril 2005;83:42-8. (Pubitemid 40094779)
49. Edelstein MC, Brzyski RG, Jones GS, Simonetti S, Muasher SJ. Equivalency of human menopausal gonadotropin and follicle-stimulating hormone stimulation after gonadotropin-releasing hormone agonist suppression. Fertil Steril 1990;53:103-6.
50. Mercan R, Mayer JF, Walker D, Jones S, Oehninger S, Toner JP et al. Improved oocyte quality is obtained with follicle stimulating hormone alone than with follicle stimulating hormone/human menopausal gonadotrophin combination. Hum Reprod 1997;12:1886-9. (Pubitemid 27462463)
51. Oehninger S, Barroso G, Jones D, Muasher S. Recombinant and urinary FSH preparations: a comperative analysis of multifollicular development and IVF/ICSI outcome in different categories of ovarian responders. Middle East Fertility Society (MEFS) Journal 1999;4:114-22. (Pubitemid 29377024)
52. Shoham Z. The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation. Fertil Steril 2002;77:1170-7. (Pubitemid 34626325)
53. Meldrum DR, Schoolcraft W. Microdose flare versus antagonist for poor responders. Fertil Steril 2010;93:e35.
54. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 2006;3:CD001750.
55. Tarlatzis BC, Fauser BC, Kolibianakis EM, Diedrich K, Rombauts L, Devroey P. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update 2006; 12:333-40.
56. Kolibianakis EM, Zikopoulos K, Smitz J, Camus M, Tournaye H, Van Steirteghem AC et al. Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization. Fertil Steril 2004;82:223-6. (Pubitemid 38968805)
57. Kolibianakis EM, Kalogeropoulou L, Griesinger G, Papanikolaou EG, Papadimas J, Bontis J et al. Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis. Hum Reprod Update 2007;13:445-52. (Pubitemid 47299851)
58. Kolibianakis EM, Venetis CA, Kalogeropoulou L, Papanikolaou E, Tarlatzis BC. Fixed versus flexible gonadotropin-releasing hormone antagonist administration in in vitro fertilization: a randomized controlled trial. Fertil Steril [In Press].
59. Al-Inany H, Aboulghar MA, Mansour RT, Serour GI Optimizing GnRH antagonist administration: meta-analysis of fixed versus flexible protocol. Reprod Biomed Online 2005;10:567-70. (Pubitemid 40645532)
60. Bodri D, Sunkara SK, Coomarasamy A. Gonadotropin-releasing hormone agonists versus antagonists for controlled ovarian hyperstimulation in oocyte donors: a systematic review and meta-analysis. Fertil Steril 2011;95:164-9.
61. Gonen Y, Jacobson W, Casper RF. Gonadotropin suppression with oral contraceptives before in vitro fertilization. Fertil Steril 1990;53:282-7. (Pubitemid 20076357)
62. Smulders B, van Oirschot SM, Farquhar C, Rombauts L, Kremer JA. Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database Syst Rev 2010;(1):CD006109.
63. Griesinger G, Kolibianakis EM, Venetis C, Diedrich K, Tarlatzis B. Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis. Fertil Steril 2010;94:2382-4.
64. The European Recombinant Human Chorionic Gonadotropin Study Group. Induction of final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment - recombinant HCG versus urinary HCG. Hum Reprod 2000;15:1446-1451.
65. Damario MA, Barmat L, Liu HC, Davis OK, Rosenwaks Z. Dual suppression with oral contraceptives and gonadotrophin releasinghormone agonists improves invitro fertilization outcome in high responder patients. Hum Reprod 1997;12:2359-65. (Pubitemid 27522187)
66. Sterrenburg MD, Veltman-Verhulst SM, Eijkemans MJ, Hughes EG, Macklon NS, Broekmans FJ et al. Clinical outcomes in relation to the daily dose of recombinant follicle-stimulating hormone for ovarian stimulation in in vitro fertilization in presumed normal responders younger than 39 years: a meta-analysis. Hum Reprod Update [In press].
67. Stadtmauer LA, Wong BC, Oehninger S. Should patients with polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome - beyond ovulation induction. Hum Reprod 2002;17:3016-26.
68. Tso LO, Costello MF, Albuquerque LE, Andriolo RB, Freitas V. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2009;(2):CD006105.
69. Arslan M, Bocca S, Arslan EO, Duran HE, Stadtmauer L, Oehninger S. Cumulative exposure to high estradiol levels during the follicular phase of IVF cycles negatively affects implantation. J Assist Reprod Genet 2007;24:111-7.
70. Oehninger S. Revealing the enigmas of implantation: what is the true impact of ovarian hyperstimulation? Fertil Steril 2008;89:27-30.
71. Venetis CA, Kolibianakis EM, Toulis KA, Goulis DG, Papadimas I, Tarlatzis BC. Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and metaanalysis. Fertil Steril 2011;95:188-96.
72. Youssef MA, van Wely M, Hassan MA, Al-Inany HG, Mochtar M, Khattab S et al. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Hum Reprod Update 2010;16:459-66.
73. Humaidan P, Papanikolaou EG, Tarlatzis BC. GnRHa to trigger final oocyte maturation: a time to reconsider. Hum Reprod 2009;24:2389-94.
74. Engmann L, Benadiva C. Ovarian hyperstimulation syndrome prevention strategies: Luteal support strategies to optimize pregnancy success in cycles with gonadotropin-releasing hormone agonist ovulatory trigger. Semin Reprod Med 2010;28:506-12.
75. Muasher SJ. Treatment of low responders. J Assist Reprod Genet 1993;10:112-4.
76. Oehninger S, Hinsch E, Pfisterer S, Veeck LL, Kolm P, Schill WB, Hodgen GD, Hinsch KD. Use of a specific zona pellucida (ZP) protein 3 antiserum as a clinical marker for human ZP integrity and function. Fertil Steril 1996;65:139-45.
77. Greenhouse S, Rankin T, Dean J. Genetic causes of female infertility: targeted mutagenesis in mice. Am J Hum Genet. 1998;62:1282-7.
78. Scott RT, Navot D. Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization. Fertil Steril 1994;61:880-5.
79. Bromer JG, Cetinkaya MB, Arici A. Pretreatments before the induction of ovulation in assisted reproduction technologies: evidence-based medicine in 2007. Ann N Y Acad Sci 2008;1127:31-40.
80. Barroso G, Oehninger S, Monzo A, Kolm P, Gibbons WE, Muasher SJ. High FSH:LH ratio and low LH levels in basal cycle day 3: impact on follicular development and IVF outcome. J Assist Reprod Genet 2001;18:499-505.
81. Dragisic KG, Davis OK, Fasouliotis SJ, Rosenwaks Z. Luteal estradiol patch/GnRH-antagonist suppression prior to gonadotropin stimulation improves IVF outcome in poor responders: A novel approach. Fertil Steril 2004;82(Suppl 2):S124.
82. Weitzman VN, Engmann L, DiLuigi A, Maier D, Nulsen J, Benadiva C. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes. Fertil Steril 2009;92:226-30.
83. Nilsson L, Andersen AN, Lindenberg S, Hausken J, Andersen CY, Kahn JA. Ganirelix for luteolysis in poor responder patients undergoing IVF treatment: a Scandinavian multicenter extended pilot study'. Acta Obstet Gynecol Scand 2010;89:828-31.
84. Elassar A, Mann JS, Engmann L, Nulsen J, Benadiva C. Luteal phase estradiol versus luteal phase estradiol and antagonist protocol for controlled ovarian stimulation before in vitro fertilization in poor responders. Fertil Steril 2011;95:324-6.
85. Feigenberg T, Simon A, Ben-Meir A, Gielchinsky Y, Laufer N. Role of androgens in the treatment of patients with low ovarian response. Reprod Biomed Online 2009;19:888-98.
86. Mochtar MH, Van der Veen, Ziech M, van Wely M. Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev 2007;(2):CD005070.
87. Kolibianakis EM, Venetis CA, Diedrich K, Tarlatzis BC, Griesinger G. Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated by in-vitro fertilization: a systematic review and meta-analysis. Hum Reprod Update 2009;15:613-22.
88. Pandian Z, McTavish AR, Aucott L, Hamilton MP, Bhattacharya S. Interventions for 'poor responders' to controlled ovarian hyper stimulation (COH) in invitro fertilisation (IVF). Cochrane Database Syst Rev 2010;(1):CD004379.
89. Williams SC, Gibbons WE, Muasher SJ, Oehninger S. Minimal ovarian hyperstimulation for in vitro fertilization using sequential clomiphene citrate and gonadotropin with or without the addition of a gonadotropin-releasing hormone antagonist. Fertil Steril 2002;78:1068-72.
90. Fauser BC, Nargund G, Andersen AN, Norman R, Tarlatzis B, Boivin J et al. Mild ovarian stimulation for IVF: 10 years later. Hum Reprod 2010;25:2678-84.
91. Baart EB, Martini E, Eijkemans MJ, Van Opstal D, Beckers NG, Verhoeff A, Macklon NS, Fauser BC. Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial. Hum Reprod 2007;22:980-8.
92. Van Voorhis BJ, Thomas M, Surrey ES, Sparks A. What do consistently high-performing in vitro fertilization programs in the U.S. do? Fertil Steril 2010;94:1346-9.
93. Fauzdar A, Haider A, Kumar A. Effect of gonadotropins on chromosome aneuploidy, chromosome mosaicism & sex ratio in mouse preimplantation embryos. Indian J Med Res 2009;129:669-75.
94. Grace KS, Sinclair KD. Assisted reproductive technology, epigenetics, and long-term health: a developmental time bomb still ticking. Semin Reprod Med 2009;27:409-16.
95. Beydoun HA, Sicignano N, Beydoun MA, Matson DO, Bocca S, Stadtmauer L et al. A cross-sectional evaluation of the first cohort of young adults conceived by in vitro fertilization in the United States. Fertil Steril 2010;94:2043-9.
96. Laprise SL. Implications of epigenetics and genomic imprinting in assisted reproductive technologies. Mol Reprod Dev 2009;76:1006-18.
97. Fauser BC, Mannaerts BM, Devroey P, Leader A, Boime I, Baird DT. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Hum Reprod Update 2009;15:309-21.
98. Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman-Boon PC, Fauser BC et al. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 2009;24:3063-72.
99. qOehninger S. Strategies for fertility preservation in female and male cancer survivors. J Soc Gynecol Investig 2005;12:222-31.
100. qAta B, Chian RC, Tan SL. Cryopreservation of oocytes and embryos for fertility preservation for female cancer patients. Best Pract Res Clin Obstet Gynaecol 2010;24:101-12.
101. Oktay K, Türkçüoglu I, Rodriguez-Wallberg KA. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod Biomed Online 2010;20:783-8.
102. Lamar CA, DeCherney AH. Fertility preservation: state of the science and future research directions. Fertil Steril. 2009;91:316-9.